Kyverna Therapeutics Inc (KYTX) Stock Price, Quote & News

Company Profile

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; a...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 925 2492

Website: kyvernatx.com

Address:

5980 Horton Street, Suite 550, Emeryville, United States

bioland Apr. 24 at 8:04 PM

$KYTX I'd like to see the filings. Hard to believe this is all ATM.

1 · Reply

BioFiend Apr. 24 at 2:33 PM

$KYTX Hope everyone bought when it hit its resistance at 8.60-8.90

1 · Reply

Unkn0wnKG Apr. 24 at 1:34 PM

$KYTX why do the large orders only seem to come late in the day? They start picking up after lunch.

0 · Reply

RDequities Apr. 24 at 11:34 AM

$KYTX running .

0 · Reply

himu04 Apr. 24 at 3:43 AM

$KYTX when are you gonna move your ass?

0 · Reply

BioRich Apr. 23 at 9:22 PM

$KYTX Opportunity. Perfect storm today so added again. Just a smaller position.

1 · Reply

PotatoJenkins Apr. 23 at 9:10 PM

$KYTX if you’re at a loss why good news= big drop, you’re not thinking like a big shark. Selling the news after lots of retail liquidity is how the big sharks eat. Great fundamentals will bring this right back around with some patience. Meanwhile, I’m loading up. I love when the big guys oversell, leads to asymmetric opportunities.

2 · Reply

Fringe Apr. 23 at 8:10 PM

$KYTX no worries here at all. Under $10 is a gift. It can come right back in 20 min. Just be patient.

0 · Reply

Zerolag Apr. 23 at 8:03 PM

$MOH $KYTX $SRAD $VKTX save

0 · Reply

Unkn0wnKG Apr. 23 at 7:47 PM

$KYTX I mean everything is red today but still, it hurts to look at when we've got such promising news.

2 · Reply

Kyverna Therapeutics Transcript: Status update

Apr 21, 2026, 6:45 PM EDT - 5 days ago

Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting

Apr 20, 2026, 8:00 AM EDT - 6 days ago

Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks

Apr 9, 2026, 8:00 AM EDT - 17 days ago

Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026

Mar 26, 2026, 4:02 PM EDT - 4 weeks ago

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 9, 2026, 11:20 AM EDT - 6 weeks ago

Kyverna Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 5, 2026, 4:21 PM EST - 7 weeks ago

Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026

Mar 3, 2026, 8:00 AM EST - 7 weeks ago

Kyverna Therapeutics to Participate in Upcoming March Investor Conferences

Feb 24, 2026, 8:00 AM EST - 2 months ago

Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors

Feb 3, 2026, 8:00 AM EST - 2 months ago

Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer

Jan 14, 2026, 12:45 PM EST - 3 months ago

Kyverna Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 8:00 AM EST - 3 months ago

Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference

Jan 5, 2026, 8:00 AM EST - 3 months ago

Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference

Dec 17, 2025, 9:24 AM EST - 4 months ago

Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock

Dec 16, 2025, 8:06 AM EST - 4 months ago

Lightwave Logic, Kyverna Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

LWLG

Dec 15, 2025, 4:01 PM EST - 4 months ago

Kyverna Therapeutics Announces Proposed Public Offering of Common Stock

Dec 15, 2025, 8:00 AM EST - 4 months ago

Kyverna Therapeutics Transcript: Study Result

Dec 15, 2025, 6:42 AM EST - 4 months ago

Kyverna's cell therapy meets main goal of mid-stage study

Dec 15, 2025, 6:30 AM EST - 4 months ago

Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome

Dec 14, 2025, 2:30 PM EST - 4 months ago

Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome

Nov 17, 2025, 8:00 AM EST - 5 months ago

Kyverna Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 4:05 PM EST - 5 months ago

Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 10, 2025, 8:00 AM EST - 5 months ago

Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 3, 2025, 8:00 AM EST - 6 months ago

Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance

Oct 29, 2025, 8:00 AM EDT - 6 months ago

Kyverna Therapeutics Transcript: Study Update

Oct 29, 2025, 6:30 AM EDT - 6 months ago

Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025

Oct 25, 2025, 11:00 AM EDT - 6 months ago

Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025

Oct 22, 2025, 8:00 AM EDT - 6 months ago

Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis

Sep 24, 2025, 9:05 AM EDT - 7 months ago

Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS

Sep 15, 2025, 1:02 PM EDT - 7 months ago

Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025

Sep 9, 2025, 11:00 AM EDT - 8 months ago

Kyverna Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 4:05 PM EDT - 8 months ago

Kyverna Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 11:00 AM EDT - 8 months ago

Kyverna Therapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Aug 28, 2025, 11:00 AM EDT - 8 months ago

Kyverna Therapeutics Transcript: KOL Event

Aug 28, 2025, 8:00 AM EDT - 8 months ago

Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event

Aug 25, 2025, 4:02 PM EDT - 8 months ago

Kyverna Therapeutics to Present at Upcoming Investor Conferences in September

Aug 20, 2025, 3:29 PM EDT - 8 months ago

Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026

Aug 12, 2025, 4:02 PM EDT - 9 months ago

Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Jul 29, 2025, 8:30 AM EDT - 9 months ago

Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise

Jun 4, 2025, 4:55 PM EDT - 11 months ago

Kyverna Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 28, 2025, 4:02 PM EDT - 11 months ago

Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference

May 27, 2025, 3:42 PM EDT - 11 months ago

With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around?

May 13, 2025, 4:02 PM EDT - 1 year ago

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Mar 27, 2025, 4:02 PM EDT - 1 year ago

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 10, 2025, 3:00 PM EDT - 1 year ago

Kyverna Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 3, 2025, 4:05 PM EST - 1 year ago

Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference

Feb 7, 2025, 11:42 AM EST - 1 year ago

KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit

Feb 6, 2025, 1:51 PM EST - 1 year ago

Investors in Kyverna Therapeutics, Inc. Should Contact The Gross Law Firm Before February 7, 2025 to Discuss Your Rights – KYTX

Feb 5, 2025, 11:54 AM EST - 1 year ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics

Jan 13, 2025, 8:15 PM EST - 1 year ago

Kyverna Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

bioland Apr. 24 at 8:04 PM

$KYTX I'd like to see the filings. Hard to believe this is all ATM.

1 · Reply

BioFiend Apr. 24 at 2:33 PM

$KYTX Hope everyone bought when it hit its resistance at 8.60-8.90

1 · Reply

Unkn0wnKG Apr. 24 at 1:34 PM

$KYTX why do the large orders only seem to come late in the day? They start picking up after lunch.

0 · Reply

RDequities Apr. 24 at 11:34 AM

$KYTX running .

0 · Reply

himu04 Apr. 24 at 3:43 AM

$KYTX when are you gonna move your ass?

0 · Reply

BioRich Apr. 23 at 9:22 PM

$KYTX Opportunity. Perfect storm today so added again. Just a smaller position.

1 · Reply

PotatoJenkins Apr. 23 at 9:10 PM

2 · Reply

Fringe Apr. 23 at 8:10 PM

$KYTX no worries here at all. Under $10 is a gift. It can come right back in 20 min. Just be patient.

0 · Reply

Zerolag Apr. 23 at 8:03 PM

$MOH $KYTX $SRAD $VKTX save

0 · Reply

Unkn0wnKG Apr. 23 at 7:47 PM

$KYTX I mean everything is red today but still, it hurts to look at when we've got such promising news.

2 · Reply

blocktrade Apr. 23 at 7:31 PM

$KYTX sorry, but this looks like it is going back into the 7’s.

2 · Reply

HarryScrotmmm Apr. 23 at 7:28 PM

$KYTX still at a loss as to why she is down. It looked like everythig was good.

1 · Reply

Unkn0wnKG Apr. 23 at 7:23 PM

$KYTX I'm tired boss

0 · Reply

Fringe Apr. 23 at 7:05 PM

$KYTX ouch $8’s incoming. Will add more once this settles.

0 · Reply

Thrasher5699 Apr. 23 at 6:36 PM

$KYTX Losing so much money. Only on paper. Do not sell

1 · Reply

bioland Apr. 23 at 3:55 PM

$KYTX This is so predictable...they'll fk with this for as long as they can to wash us out and then let it fly up after the tutes get as much as they want. Don't fall for it.

0 · Reply

ycycyc Apr. 23 at 3:27 PM

$KYTX added all morning...will continue to add :)

0 · Reply

SwallowTheLeader Apr. 23 at 3:19 PM

$KYTX back to $10 in a few min. Hope you added at $9.35 That was a gift. This is a $20 stock in a few weeks. Easy double from here.

1 · Reply

Th3M4skedSt0nker Apr. 23 at 3:17 PM

$KYTX As of April 24, 2026, there are 67 days remaining until the end of Q2 (June 30, 2026)

0 · Reply

Th3M4skedSt0nker Apr. 23 at 3:15 PM

$KYTX will raise to range of $15 slowly and steady from a floor around $10 prior to the BLA. Smart money is accumulating now without putting too much buying pressure as they want in as cheap as possible.

0 · Reply

Unkn0wnKG Apr. 23 at 3:00 PM

$KYTX someone loan me 2 thousand more so I can pump more in, I'm capped out.

0 · Reply

Merlintrader Apr. 23 at 2:48 PM

$KYTX Kyverna Therapeutics ( $KYTX ) April 2026 Deep Dive https://merlintrader.com/kyverna-therapeutics-aprill2026-dd/

0 · Reply

Market Cap	548.40M
Revenue (ttm)	0.00
Net Income (ttm)	-161.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.11

Volume	1,489,100
Avg Vol	856,398
Day's Range	N/A - N/A
Shares Out	60.53M
Stochastic %K	15%
Beta	2.62
Analysts	Strong Sell
Price Target	$29.60